Anja K ö nig

Nature Reviews Drug Discovery 17, 310 (2018). doi:10.1038/nrd.2018.60 When Anja König started her PhD in mathematical physics at Cornell University, she hoped that a pencil and a brain was all she'd need to tackle hard science questions. Over two decades on, she has now swapped the pencil for a chequebook and moved into the much more empirical world of life sciences. As Global Head of the Novartis Venture Fund (NVF), she oversees one of the most deep-pocketed and active corporate venture capital (CVC) funds in biopharma. NVF — a financially rather than strategically driven CVC group — has around US$800 million under management and more than 40 companies in its portfolio. König spoke with Asher Mullard about the changing CVC landscape and the role of women within it.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research